ADAM17 and COVID-19: While anti-ADAM17 compounds can upregulate mACE2 expression, increasing viral binding to ACE2-positive cells, they can inhibit systemic ACE2 release in the early phase of COVID-19, reducing sACE2 and suppressing viral infectivity [45].